ACRS Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aclaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.59 |
| 52 Week High | US$5.17 |
| 52 Week Low | US$0.77 |
| Beta | 0.12 |
| 11 Month Change | 279.34% |
| 3 Month Change | 282.50% |
| 1 Year Change | 463.67% |
| 33 Year Change | -65.75% |
| 5 Year Change | 179.88% |
| Change since IPO | -58.46% |
Recent News & Updates
Recent updates
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 12
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Shareholder Returns
| ACRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 88.1% | -5.3% | -1.2% |
| 1Y | 463.7% | 8.7% | 30.4% |
Return vs Industry: ACRS exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: ACRS exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| ACRS volatility | |
|---|---|
| ACRS Average Weekly Movement | 22.6% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACRS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ACRS's weekly volatility has increased from 15% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 89 | Neal Walker | www.aclaristx.com |
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. Fundamentals Summary
| ACRS fundamental statistics | |
|---|---|
| Market cap | US$327.87m |
| Earnings (TTM) | -US$37.00m |
| Revenue (TTM) | US$27.08m |
12.1x
P/S Ratio-8.9x
P/E RatioIs ACRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACRS income statement (TTM) | |
|---|---|
| Revenue | US$27.08m |
| Cost of Revenue | US$103.99m |
| Gross Profit | -US$76.91m |
| Other Expenses | -US$39.91m |
| Earnings | -US$37.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | -284.04% |
| Net Profit Margin | -136.65% |
| Debt/Equity Ratio | 0% |
How did ACRS perform over the long term?
See historical performance and comparison